London, UK, Nashville, TN, 12 January 2006 - Following the announcement on 8 December 2005, of the licensing agreement between Protherics and AstraZeneca for the global development and commercialisation of Protherics’ anti-sepsis product CytoFabTM, it is further announced that the agreement has become effective following the expiry of the Hart-Scott-Rodino waiting period in the US. This triggers an immediate initial payment to Protherics of £16.3 million and a £7.5 million equity investment by AstraZeneca in Protherics. The agreement has further potential milestone payments worth up to £171 million and Protherics will also receive a 20 percent net royalty on the net global sales of CytoFabTM.
